{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:41:07Z","timestamp":1791218467700,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":3592,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Human Genome Sciences, Inc."},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1093\/annonc\/mdp292","type":"journal-article","created":{"date-parts":[[2009,7,25]],"date-time":"2009-07-25T00:35:29Z","timestamp":1248482129000},"page":"376-381","source":"Crossref","is-referenced-by-count":134,"title":["Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors"],"prefix":"10.1016","volume":"21","author":[{"given":"H.A.","family":"Wakelee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.I.","family":"Sikic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.L.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Miceli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.J.","family":"Ullrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.A.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.W.","family":"Tolcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdp292_bb0010","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10495-005-6060-0","article-title":"Death to the bad guys: targeting cancer via Apo2L\/TRAIL","volume":"10","author":"Bouralexis","year":"2005","journal-title":"Apoptosis"},{"key":"10.1093\/annonc\/mdp292_bb0015","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/sj.cr.7290311","article-title":"Expression of TRAIL and TRAIL receptors in normal and malignant tissues","volume":"15","author":"Daniels","year":"2005","journal-title":"Cell Res"},{"key":"10.1093\/annonc\/mdp292_bb0020","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.ejca.2005.02.018","article-title":"Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: potential targets for apoptosis induction","volume":"41","author":"Koornstra","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdp292_bb0025","first-page":"3397","article-title":"Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors","volume":"9","author":"Spierings","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdp292_bb0030","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1158\/1078-0432.CCR-05-0158","article-title":"Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer","volume":"11","author":"McCarthy","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdp292_bb0035","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.urology.2006.12.007","article-title":"Human agonistic antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 induces cytotoxicity and apoptosis in prostate cancer and bladder cancer cells","volume":"69","author":"Shimada","year":"2007","journal-title":"Urology"},{"key":"10.1093\/annonc\/mdp292_bb0040","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.canlet.2006.11.013","article-title":"Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model","volume":"251","author":"Zhang","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1093\/annonc\/mdp292_bb0045","doi-asserted-by":"crossref","first-page":"12687","DOI":"10.1074\/jbc.271.22.12687","article-title":"Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family","volume":"271","author":"Pitti","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1093\/annonc\/mdp292_bb0050","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.277.5327.818","article-title":"Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors","volume":"277","author":"Sheridan","year":"1997","journal-title":"Science"},{"key":"10.1093\/annonc\/mdp292_bb0055","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.cdd.4401187","article-title":"Apo2L\/TRAIL and its death and decoy receptors","volume":"10","author":"LeBlanc","year":"2003","journal-title":"Cell Death Differ"},{"key":"10.1093\/annonc\/mdp292_bb0060","first-page":"847","article-title":"Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo","volume":"60","author":"Nagane","year":"2000","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdp292_bb0065","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/91000","article-title":"Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity","volume":"7","author":"Ichikawa","year":"2001","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdp292_bb0070","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1158\/1535-7163.MCT-06-0188","article-title":"Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies","volume":"5","author":"Gong","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdp292_bb0075","first-page":"421","article-title":"Monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo","volume":"28","author":"Zeng","year":"2006","journal-title":"Int J Oncol"},{"key":"10.1093\/annonc\/mdp292_bb0080","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2141.2005.05656.x","article-title":"Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death","volume":"130","author":"Georgakis","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdp292_bb0085","first-page":"826","article-title":"Human agonistic anti-TRAIL receptor antibodies, HGS-ETR1 and HGS-ETR2, induce apoptosis in ovarian tumor lines and their activity is enhanced by taxol and carboplatin","volume":"45","author":"Johnson","year":"2004","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1093\/annonc\/mdp292_bb0090","first-page":"193","article-title":"TRAIL-R2 mAb, a human agonistic monoclonal antibody to tumor necrosis factor-related apoptosis inducing ligand receptor 2, induces apoptosis in human tumor cells","volume":"44","author":"Alderson","year":"2003","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1093\/annonc\/mdp292_bb0095","first-page":"123","article-title":"TRAIL-R2 mAB, a human agonistic monoclonal antibody to tumor necrosis factor-related apoptosis inducing ligand receptor 2, affects tumor growth and induces apoptosis in human tumor xenograft models in vivo","volume":"44","author":"Humphreys","year":"2003","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1093\/annonc\/mdp292_bb0100","doi-asserted-by":"crossref","first-page":"6187","DOI":"10.1158\/1078-0432.CCR-07-0950","article-title":"Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers","volume":"13","author":"Plummer","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdp292_bb0105","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdp292_bb0110","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.2004.07.099","article-title":"Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group","volume":"22","author":"Scher","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp292_bb0115","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm Res"},{"key":"10.1093\/annonc\/mdp292_bb0120","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1476-4598-6-66","article-title":"Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin","volume":"6","author":"Belyanskaya","year":"2007","journal-title":"Mol Cancer"},{"key":"10.1093\/annonc\/mdp292_bb0125","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1111\/j.1349-7006.2007.00632.x","article-title":"Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression","volume":"98","author":"Wu","year":"2007","journal-title":"Cancer Sci"},{"issue":"Suppl","key":"10.1093\/annonc\/mdp292_bb0130","first-page":"133","article-title":"HGS-ETR2, an agonistic, TRAIL receptor 2 human monoclonal antibody, synergizes with chemotherapeutic agents to increase in vitro cytotoxicity and induce tumor regression in vivo tumor xenografts","volume":"11","author":"Humphreys","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdp292_bb0135","first-page":"539","article-title":"Drug evaluation: lexatumumab, an intravenous human agonistic mAb targeting TRAIL receptor 2","volume":"8","author":"Marini","year":"2006","journal-title":"Curr Opin Mol Ther"},{"key":"10.1093\/annonc\/mdp292_bb0140","doi-asserted-by":"crossref","first-page":"612s","DOI":"10.1200\/jco.2007.25.18_suppl.14006","article-title":"A phase Ib study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI","volume":"25","author":"Sikic","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419387460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419387460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/21\/2\/376\/922041\/mdp292.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:15:19Z","timestamp":1624518919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419387460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S0923753419387460"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdp292","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}